Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Ke, Shan ^a   Ding, Xue mei ^a   Kong, Jian ^a   Gao, Jun ^a   Wang, Shao hong ^a   Cheng, Yan ^a   Sun, Wen bing ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; GELATINASE B; INTERLEUKIN 6; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; GROWTH RATE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LOW TEMPERATURE; LOW TEMPERATURE PROCEDURES; LUNG METASTASIS; MINIMAL RESIDUAL DISEASE; NONHUMAN; PROTEIN EXPRESSION; RABBIT; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOFREQUENCY ABLATION; SQUAMOUS CELL CARCINOMA; TARGET ORGAN; TEMPERATURE DEPENDENCE; TISSUE LEVEL; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CATHETER ABLATION; CELL PROLIFERATION; COLD; DISEASE COURSE; ENZYMOLOGY; LIVER TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; METHODOLOGY; PATHOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CELL PROLIFERATION; COLD TEMPERATURE; DISEASE PROGRESSION; HEPATOCYTE GROWTH FACTOR; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; LIVER NEOPLASMS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 9; NEOPLASM, RESIDUAL; PROLIFERATING CELL NUCLEAR ANTIGEN; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954962476     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-73     Document Type: Article

References (41)

1. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009, 3(4):353-367. 10.1586/egh.09.35, 19673623.
2. Sun WB. How is radiofrequency ablation going in treating hepatocellular carcinoma in China?. Austral-Asian Journal of Cancer 2008, 7(4):221-224.
3. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 2009, 249(1):20-25. 10.1097/SLA.0b013e31818eec29, 19106671.
4. Rhim H, Kim YS, Choi D, Lim HK, Park K. Percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of 80 patients treated with two consecutive sessions. Eur Radiol 2008, 18(7):1442-1448. 10.1007/s00330-008-0902-4, 18389252.
5. Thanos L, Mylona S, Galani P, Pomoni M, Pomoni A, Koskinas I. Overcoming the heat-sink phenomenon: successful radiofrequency thermal ablation of liver tumors in contact with blood vessels. Diagn Interv Radiol 2008, 14(1):51-56.
6. Zhou XP, Yang GS, Cong WM, Lu JH, Zhang SH, Zong M. Retrospective and prospective study on micrometastasis in liver parenchyma surrounding PLC. Chinese Journal of Hepatobiliary Surgery 2005, 11(8):510-514.
7. Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, Nakagawa T, Inoue K. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol 2001, 13(3):291-294. 10.1097/00042737-200103000-00014, 11293452.
8. Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, Guglielmi A. Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation. World J Gastroenterol 2004, 10(8):1137-1140.
9. Obara K, Matsumoto N, Okamoto M, Kobayashi M, Ikeda H, Takahashi H, Katakura Y, Matsunaga K, Ishii T, Okuse C, Suzuki M, Itoh F. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int 2008, 2(1):116-123. 10.1007/s12072-007-9040-3, 2716878, 19669287.
10. Kasugai H, Osaki Y, Oka H, Kudo M, Seki T. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Oncology 2007, 72(Suppl 1):72-75. 10.1159/000111710, 18087185.
11. Kim TJ, Moon WK, Cha JH, Goo JM, Lee KH, Kim KH, Lee JW, Han JG, Weinmann HJ, Chang KH. VX2 carcinoma in rabbits after radiofrequency ablation: comparison of MR contrast agents for help in differentiating benign periablational enhancement from residual tumor. Radiology 2005, 234(2):423-430. 10.1148/radiol.2342031456, 15591437.
12. Gu T, Li CX, Feng Y, Wang Q, Li CH, Li CF. Trans-arterial gene therapy for hepatocellular carcinoma in a rabbit model. World J Gastroenterol 2007, 13(14):2113-2117.
13. Martinez C, Vicente V, Yanez MJ, Garcia JM, Canteras M, Alcaraz M. Experimental model of pulmonary metastasis treatment with IFNalpha. Cancer Lett 2005, 225(1):75-83. 10.1016/j.canlet.2004.11.047, 15922859.
14. Carlsson G, Gullberg B, Hafstrom L. Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 1983, 105(1):20-23. 10.1007/BF00391826, 6833336.
15. Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchiano A, Fornari F, Quaretti P, Tolla GD, Ambrosi C, Mazzaferro V, Blum HE, Bartolozzi C. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000, 217(1):119-126.
16. Stoimenov I, Helleday T. PCNA on the crossroad of cancer. Biochem Soc Trans 2009, 37(Pt 3):605-613. 10.1042/BST0370605, 19442257.
17. Stroescu C, Dragnea A, Ivanov B, Pechianu C, Herlea V, Sgarbura O, Popescu A, Popescu I. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis 2008, 17(4):411-417.
18. Ballardini G, Groff P, Zoli M, Bianchi G, Giostra F, Francesconi R, Lenzi M, Zauli D, Cassani F, Bianchi F. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J Hepatol 1994, 20(2):218-222. 10.1016/S0168-8278(05)80061-3, 7911817.
19. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009, 27(31):5287-5297. 10.1200/JCO.2009.23.5556, 19738110.
20. Li X, Wu JF. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs). Recent Pat Anticancer Drug Discov 5(2):109-141. 10.2174/157489210790936234, 19951249.
21. Yang P, Yuan W, He J, Wang J, Yu L, Jin X, Hu Y, Liao M, Chen Z, Zhang Y. Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatol Res 2009, 39(12):1169-1177. 10.1111/j.1872-034X.2009.00563.x, 19788698.
22. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J, Zhang LJ. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 2009, 39(2):177-186. 10.1111/j.1872-034X.2008.00449.x, 19208038.
23. Raskopf E, Vogt A, Sauerbruch T, Schmitz V. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol 2008, 49(6):977-984. 10.1016/j.jhep.2008.07.022, 18845354.
24. Sugimachi K, Tanaka S, Terashi T, Taguchi K, Rikimaru T, Sugimachi K. The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery 2002, 131(1 Suppl):S135-141. 10.1067/msy.2002.119365, 11821800.
25. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5):1011-1027. 10.1200/JCO.2005.06.081, 15585754.
26. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009, 25(1):30-38. 10.1016/j.tig.2008.10.012, 19054589.
27. Desiderio MA. Hepatocyte growth factor in invasive growth of carcinomas. Cell Mol Life Sci 2007, 64(11):1341-1354. 10.1007/s00018-007-7050-x, 17415522.
28. You WK, McDonald DM. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 2008, 41(12):833-839.
29. Osada S, Kanematsu M, Imai H, Goshima S. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 2008, 55(82-83):544-549.
30. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005, 41(16):2502-2512. 10.1016/j.ejca.2005.08.016, 16199153.
31. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, de la Taille A. The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?. World J Urol 2007, 25(5):477-489. 10.1007/s00345-007-0175-6, 17541600.
32. Kanazawa T, Nishino H, Hasegawa M, Ohta Y, Iino Y, Ichimura K, Noda Y. Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol 2007, 264(7):815-821. 10.1007/s00405-007-0264-6, 17310346.
33. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Cancer 2007, 110(9):1911-1928. 10.1002/cncr.22999, 17849470.
34. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77(2):261-271. 10.1016/0092-8674(94)90318-2, 7513258.
35. Ponzetto C, Bardelli A, Maina F, Longati P, Panayotou G, Dhand R, Waterfield MD, Comoglio PM. A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. Mol Cell Biol 1993, 13(8):4600-4608. 360084, 7687741.
36. Lee WJ, Chen WK, Wang CJ, Lin WL, Tseng TH. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol 2008, 226(2):178-191. 10.1016/j.taap.2007.09.013, 17961621.
37. Lee KH, Choi EY, Kim MK, Hyun MS, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, Kim JR. Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines. Exp Mol Med 2006, 38(1):27-35.
38. Lee KH, Kim JR. Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells. Clin Exp Metastasis 2009, 26(7):685-692. 10.1007/s10585-009-9266-7, 19526316.
39. Zeng Q, Chen S, You Z, Yang F, Carey TE, Saims D, Wang CY. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J Biol Chem 2002, 277(28):25203-25208. 10.1074/jbc.M201598200, 11994287.
40. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 2007, 97(3):368-377. 10.1038/sj.bjc.6603884, 2360323, 17667909.
41. Toschi L, Janne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 2008, 14(19):5941-5946. 10.1158/1078-0432.CCR-08-0071, 18829470.